Athira Says Phase II Alzheimer’s Miss Will Inform Ongoing Phase III Study
Athira hoped a small Phase II study would show a benefit on working memory processing speed, but it missed its primary and all secondary endpoints, reducing confidence in the Phase III program.
You may also be interested in...
An unblinded interim efficacy analysis by a DMC recommended a Phase II/III study testing fosgonimeton in Alzheimer's patients should continue.
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.